WallStreetZenWallStreetZen

NASDAQ: VYGR
Voyager Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VYGR past earnings growth

How has VYGR's earnings growth performed historically?
Company
N/A
Industry
16.33%
Market
40.59%
VYGR's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VYGR's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

VYGR past revenue growth

How has VYGR's revenue growth performed historically?
Company
124.58%
Industry
112.01%
Market
13.97%
VYGR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VYGR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VYGR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VYGR earnings and revenue history

Current Revenue
$158.4M
Current Earnings
$52.3M
Current Profit Margin
33%

VYGR Return on Equity

Current Company
32.1%
Current Industry
15.6%
Current Market
-9.5%
VYGR's Return on Equity (32.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VYGR announces earnings.

VYGR Return on Assets

Current Company
18.9%
Current Industry
2.2%
VYGR is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VYGR Return on Capital Employed

Current Company
21.94%
Current Industry
17.7%
VYGR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VYGR vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VYGR$158.40M$55.06M$52.31M+67.66%+62.40%
CGEM$0.00-$157.71M-$156.14M-100.00%N/A
ABUS$22.24M-$73.39M-$75.47M+26.74%N/A
QURE$111.90M-$190.47M-$228.47M+55.62%N/A
GRCL$0.00-$72.82M-$83.40M-100.00%N/A
View Top Biotech Stocks

Voyager Therapeutics Earnings & Revenue FAQ

What were VYGR's earnings last quarter?

On Invalid Date, Voyager Therapeutics (NASDAQ: VYGR) reported Q3 2023 earnings per share (EPS) of -$0.59, up 228.26% year over year. Total Voyager Therapeutics earnings for the quarter were -$25.90 million. In the same quarter last year, Voyager Therapeutics's earnings per share (EPS) was $0.46.

If you're new to stock investing, here's how to buy Voyager Therapeutics stock.

What was VYGR's earnings growth in the past year?

As of Q4 2023, Voyager Therapeutics's earnings has grown year over year. Voyager Therapeutics's earnings in the past year totalled $52.31 million.

What was VYGR's revenue last quarter?

On Invalid Date, Voyager Therapeutics (NASDAQ: VYGR) reported Q3 2023 revenue of $4.61 million up 88.77% year over year. In the same quarter last year, Voyager Therapeutics's revenue was $41.09 million.

What was VYGR's revenue growth in the past year?

As of Q4 2023, Voyager Therapeutics's revenue has grown 124.58% year over year. This is 12.58 percentage points higher than the US Biotechnology industry revenue growth rate of 112.01%. Voyager Therapeutics's revenue in the past year totalled $158.40 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.